| How to Identify Advanced Fibrosis in Adult Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) Using Ultrasound Elastography—A … MG Taru, L Neamti, V Taru, LM Procopciuc, B Procopet, M Lupsor-Platon Diagnostics 13 (4), 788, 2023 | 10 | 2023 |
| Validation and performance of Chronic Liver Disease Questionnaire (CLDQ-RO) in the Romanian population V Taru, MG Indre, MD Ignat, A Forgione, T Racs, BA Olar, O Farcau, ... J Gastrointestin Liver Dis 30 (2), 240-246, 2021 | 4 | 2021 |
| Non-dental oral cavity findings in gastroesophageal reflux disease: a systematic review and meta-analysis MG Indre, D Sampelean, V Taru, A Cozma, D Sampelean, MV Milaciu, ... Journal of Mind and Medical Sciences 8 (1), 60-70, 2021 | 3 | 2021 |
| Natural history of patients with NAFLD-associated compensated advanced chronic liver disease stratified according to severity of portal hypertension R Paternostro, WJ Kwanten, BS Hofer, G Semmler, A Bagdadi, I Luzko, ... Zeitschrift für Gastroenterologie 61 (05), P31, 2023 | 1 | 2023 |
| WED-332 FASTand Agile-the MASLD Drift: validation of Agile 3+, Agile 4 and FAST scores in 246 biopsy-proven MASLD patients of prevalent caucasian origin MG Taru, C Tefas, L Neamti, I Minciuna, V Taru, A Maniu, I Rusu, ... Journal of Hepatology 80, S555-S556, 2024 | | 2024 |
| THU-540 Characterization of in vivo mouse models of regressive fibrosis and resolving portal hypertension K Bonitz, P Königshofer, B Hofer, O Petrenko, T Sorz, V Taru, ... Journal of Hepatology 80, S267, 2024 | | 2024 |
| WED-122-YI The soluble guanylate cyclase pathway is dysregulated in rodent models of cirrhosis and portal hypertension T Sorz-Nechay, K Brusilovskaya, P Konigshofer, B Hofer, O Petrenko, ... Journal of Hepatology 80, S197, 2024 | | 2024 |
| WED-125 Differential regulation of soluble guanylate cyclase signaling during liver fibrosis regression T Sorz-Nechay, K Brusilovskaya, P Königshofer, B Hofer, O Petrenko, ... Journal of Hepatology 80, S198, 2024 | | 2024 |
| WED-089-YI Characterising the hemodynamic and pro-inflammatory profile of a CCl4/LPS-induced acute-on-chronic liver failure (ACLF) rat model V Taru, T Sorz-Nechay, B Hofer, O Petrenko, P Königshofer, K Bonitz, ... Journal of Hepatology 80, S186, 2024 | | 2024 |
| THU-071 Impact of underlying portal hypertension and systemic inflammation on acute-on-chronic liver failure (ACLF) severity and outcome V Taru, G Kramer, L Balcar, B Hofer, M Schwarz, N Dominik, L Hartl, ... Journal of Hepatology 80, S165, 2024 | | 2024 |
| Hepatic venous pressure gradient predicts risk of hepatic decompensation and liver-related mortality in patients with MASLD R Paternostro, WJ Kwanten, BS Hofer, G Semmler, A Bagdadi, I Luzko, ... Journal of hepatology, 2024 | | 2024 |
| FAST and Agile–the MASLD drift: Validation of Agile 3+, Agile 4 and FAST scores in 246 biopsy-proven NAFLD patients meeting MASLD criteria of prevalent caucasian origin MG Taru, C Tefas, L Neamti, I Minciuna, V Taru, A Maniu, I Rusu, ... Plos one 19 (5), e0303971, 2024 | | 2024 |
| Auswirkungen von portaler Hypertension und systemischer Entzündung auf Schweregrad und Prognose des akut-auf-chronischen Leberversagens (ACLF) G Kramer, V Taru, L Balcar, BS Hofer, M Schwarz, N Dominik, L Hartl, ... Zeitschrift für Gastroenterologie 62 (05), P59, 2024 | | 2024 |
| An Interdisciplinary Approach to Alcohol Use Disorders: What Hepatologists Can Do in a Resource-Limited Setting A Fodor, A Nicoara, M Taru, V Taru, A Bumbu, H Stefanescu Alcohol and Alcohol-related Diseases, 1429-1439, 2023 | | 2023 |
| DECIPHERING OF THE HEPATIC SINGLE-CELL INTERACTOME IN PRIMARY SCLEROSING CHOLANGITIS O Petrenko, C Mangana, T Sorz, BS Hofer, B Simbrunner, K Zinober, ... HEPATOLOGY 78, S2044-S2046, 2023 | | 2023 |
| DIAGNOSTIC ACCURACY OF VCTE AND 2D-SWE IN BIOPSYPROVEN NAFLD AND PERFORMANCE OF TWO-STEP APPROACHES TO PREDICT ADVANCED FIBROSIS MG Taru, DC Leucuta, L Neamti, A Maniu, V Taru, B Petrushev, I Rusu, ... HEPATOLOGY 78, S791-S792, 2023 | | 2023 |
| NOVEL NON-INVASIVE SCORES THAT PREDICT FIBROSIS HAVE GREAT PERFORMANCE IN IDENTIFYING NASH PATIENTS AT RISK FOR DECOMPENSATION. V Taru, MG Taru, B Petrushev, I Rusu, H Ștefănescu, A Fodor, M Ignat, ... Journal of Gastrointestinal & Liver Diseases 32, 2023 | | 2023 |
| Systemic inflammation remains a critical determinant of the dynamic component of portal hypertension in abstinent patients with alcohol-related cirrhosis B Hofer, B Simbrunner, K Zinober, G Semmler, P Königshofer, T Sorz, ... Journal of Hepatology 78, S289, 2023 | | 2023 |
| Recently validated non-invasive tests for liver fibrosis assessment have great performance in identifying NASH patients at risk for decompensation V Taru, MG Taru, B Petrushev, R Ioana, H Stefanescu, A Fodor, MD Ignat, ... Journal of Hepatology 78, S295-S296, 2023 | | 2023 |
| Distinct patterns of hepatic and systemic inflammation in different types/aetiologies of liver disease B Hofer, B Simbrunner, P Königshofer, K Zinober, G Semmler, T Sorz, ... Journal of Hepatology 78, S222-S224, 2023 | | 2023 |
